| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04238091 Details | 2022-03-21 Interventional | 2 | 0 | Anti-Bacterial … Alopecia Alopecia Areata Alopecia Totali… Alopecia Univer… | Investigator is no longer interested in moving forward with this study - | |||
| NCT02999633 2016-002739-14 Details | 2022-03-21 Interventional | 2 | 14 | Acetaminophen BB 1101 Dexamethasone Dexamethasone a… Diphenhydramine Promethazine Ranitidine Ranitidine bism… Leukemia Leukemia, Lymph… Lymphoma Precursor Cell … Precursor T-Cel… T-cell Type Acu… T-lymphoblastic… | Due to an unsatisfactory benefit/risk ratio, as specified in & 14.8.1 of the protocol, Sanofi
decided to stop enrollment and terminate ACT14596 prematurely - | |||
| NCT02654314 Details | 2022-03-21 Interventional | 3 | 277 | Melatonin Delirium | Lack of resources to complete the study. Descriptive statistics for the outcome measures
collected are provided. - | |||
| NCT04656691 Details | 2022-03-18 Interventional | 4 | 139 | Bamlanivimab COVID-19 Covid19 | In April 2021 FDA revoked the Emergency Use Authorization after determining that the known and
potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and
potential risks for its authorized use. - | |||
| NCT04555096 Details | 2022-03-18 Interventional | 2 | 16 | Avasopasem mang… COVID-19 Critical Illnes… Infections Covid19 SARS-CoV-2 Infe… | Participants are no longer receiving intervention Study was terminated early due to the inability to enroll critically ill COVID 19 patients as the height of the pandemic was over and the sites that were open for enrollment to the clinical study were no longer treating these types of patients. | |||
| NCT01388920 Details | 2022-03-18 Interventional | 2 | 3 | Tesamorelin Cachexia Lung Diseases Lung Diseases, … Muscular Atroph… Pulmonary Disea… Wasting Syndrom… Chronic Obstruc… | The study was terminated based on a non-safety related corporate decision. - | |||
| NCT03735290 Details | 2022-03-16 Interventional | 1 | 21 | Pembrolizumab Adenocarcinoma Carcinoma, Squa… Squamous Cell C… Carcinoma, Squa… Gastric Adenoca… Gastroesophagea… Non-small Cell … | Decision made not to move to Phase 2 - | |||
| NCT02932579 Details | 2022-03-16 Interventional | 4 | 59 | Acetaminophen Ibuprofen Oxycodone Toothache Pain | Study was halted permanently due to enrollment and logistic issues. - | |||
| NCT01452152 Details | 2022-03-16 Interventional | 4 | 9 | Clopidogrel Prasugrel Hydro… Acute Coronary … Cardiovascular … | Terminated by study sponsor. The study was terminated early by the sponsor due to low enrollment. | |||
| NCT05254808 Details | 2022-03-15 Interventional | 3 | 13 | Fosfomycin Nitrofurantoin Cystitis Urinary Tract I… | Insufficient participating sites, and insufficient participants from participating sites mainly
due to COVID-19 workload. The number of necessary participants could not be reached within the
anticipated timelines and the allocated budget. - | |||
| NCT04441385 2020-002011-21 Details | 2022-03-11 Interventional | 2 | 60 | Maraviroc COVID-19 | lack of viability - | |||
| NCT02356458 2014-003893-17 Details | 2022-03-11 Interventional | 1/2 | 58 | Bortezomib Ibrutinib Lymphoma Lymphoma, Mantl… Mantle Cell Lym… | SAKK Board decision of 14th November 2020 due to financial reasons. - | |||
| NCT05051150 Details | 2022-03-10 Interventional | 4 | 18 | Epinephrine Epinephryl bora… Racepinephrine Hypotension Cesarean Sectio… Post-spinal Hyp… | tachycardia and arrhythmia in the high doses groups 0.05 and 0.07 necessitate stopping the
infusion - | |||
| NCT04990778 Details | 2022-03-10 Interventional | 2 | 0 | Venetoclax Lymphoma Lymphoma, Mantl… Recurrent Mantl… Refractory Mant… | PI Request - | |||
| NCT04324021 2020-001167-93 Details | 2022-03-10 Interventional | 2/3 | 16 | Interleukin 1 R… Infections SARS-CoV-2 | Standard of care evolved during the timeframe of the study and had critical impact on
recruitment.
Early termination was not based on safety reasons but due to the reasons mentoined above.
The ongoing patients were completed. - | |||
| NCT04209621 Details | 2022-03-09 Interventional | 2 | 3 | Ibrutinib Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… Small Lymphocyt… | Due to unexpected sudden death on study. - | |||
| NCT03592407 Details | 2022-03-08 Interventional | 2 | 0 | Pembrolizumab Adenocarcinoma Esophageal Squa… Esophageal Aden… Gastroesophagea… | Safety concerns - | |||
| NCT05267977 Details | 2022-03-07 Interventional | 1/2 | - | Cephalosporins First Generatio… Fractures, Bone Fractures, Open Lower Extremity… | - - | |||
| NCT03549650 Details | 2022-03-04 Interventional | 2 | 3 | Pentosan Sulfur… Lower Urinary T… Urinary Bladder… BCG Bladder Carcino… | Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided
to terminate the study. - | |||
| NCT02570503 Details | 2022-03-04 Interventional | 4 | 64 | Clonidine Epinephrine Ketorolac Ropivacaine Osteoarthritis,… Pain, Postopera… | Study's primary aims are no longer clinically impactful, as intrathecal morphine has fallen out
of favor and replaced with different agents so that outpatient/23 hr surgery is more
predictably achievable. - |